Pyxis Oncology (NASDAQ:PYXS) Issues Quarterly Earnings Results

Pyxis Oncology (NASDAQ:PYXS) released its earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02), Zacks reports.

Pyxis Oncology Price Performance

PYXS stock traded down $0.41 during midday trading on Thursday, reaching $2.21. 1,062,627 shares of the stock were exchanged, compared to its average volume of 571,989. Pyxis Oncology has a 52 week low of $0.97 and a 52 week high of $5.55. The company has a fifty day moving average price of $1.70 and a 200 day moving average price of $2.30. The stock has a market capitalization of $138.90 million, a PE ratio of -1.71 and a beta of 1.43.

Analysts Set New Price Targets

A number of research firms have recently commented on PYXS. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, March 24th. Stifel Nicolaus lowered their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Wall Street Zen raised shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 13th. Finally, Wedbush initiated coverage on shares of Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.83.

Institutional Trading of Pyxis Oncology

A number of hedge funds have recently made changes to their positions in the company. XTX Topco Ltd grew its holdings in shares of Pyxis Oncology by 1,533.0% during the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after purchasing an additional 271,334 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Pyxis Oncology during the 4th quarter worth approximately $86,000. Quadrature Capital Ltd acquired a new stake in Pyxis Oncology during the 4th quarter worth approximately $116,000. Maia Wealth LLC bought a new stake in Pyxis Oncology during the 4th quarter worth approximately $25,000. Finally, Engineers Gate Manager LP acquired a new position in Pyxis Oncology in the 4th quarter valued at approximately $26,000. 39.07% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.